The Latest Breaking News from Pfizer

Pfizer's Vitiligo Pill Shows Promise as Doctors Explain Why the Condition Is More Than Skin Deep

Pfizer says Phase 3 trials show Litfulo helped restore skin pigmentation in nonsegmental vitiligo, marking a promising advance in treatment.

Medical Daily · Aug 4

SpaceX Could Swing $204 Billion After Earnings

Earnings are set to hit the tape in a tight window on Tuesday, and the options market is already sketching out how much volatility traders expect once results and guidance land, according to Benzinga Pro.

Benzinga · Aug 3

Pregnant Patients Caught Between Two Vaccine Schedules Now Have Infant Hospitalization Numbers to Bring to the Appointment

ACOG and CDC guidance on pregnancy vaccines now differ. New research shows maternal RSV vaccination cut infant hospitalizations by about 68 percent.

Medical Daily · Jul 31

Pfizer and the $200 Billion-Dollar Cardiovascular Market

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the rapidly growing $200 billion heart disease market.

International Business Times · Jul 23

When can a power company take your land for data center infrastructure?

The artificial intelligence boom in the United States is being matched by a data center building boom. There are more than 3,000 data centers in the U.S. and another 1,500 in development, according to a Pew Research Center analysis.

The Conversation · Jul 16

Here's What to Expect From Pfizer's Next Earnings Report

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.

Barchart · Jul 14

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

MarketBeat · Jul 13

‘I have an inoperable brain tumour after having the contraceptive jab’

A study found women who used the contraceptive injection for at least a year are 5.6 times more likely to develop meningioma brain tumours

The Independent UK · Jul 12

Why companies are paying a premium for battle-tested CFOs—and Nike’s struggling turnaround shows what that costs

David Denton, Nike’s new CFO, is coming from Pfizer—underscoring how far companies will go to recruit proven top finance chiefs.

Fortune · Jul 10

New York high-rise scare exposes the challenges of converting offices into housing

City officials have not determined what caused the columns to buckle but engineers believe the failure likely resulted from the added load

The Independent UK · Jul 10